Forest Laboratories

Furiex Pharmaceuticals, Inc. is a drug development company based in Morrisville, North Carolina, that specializes in compound partnering services primarily in the United States. The company collaborates with pharmaceutical and biotechnology firms to enhance the potential of their drug candidates through innovative clinical development strategies. Among its products in development is Eluxadoline, a mu opioid receptor agonist and delta opioid receptor antagonist currently undergoing Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome. Additionally, Furiex is advancing Avarofloxacin, a fluoroquinolone antibiotic that is prepared for Phase III trials aimed at addressing acute bacterial skin and skin structure infections.

Aptalis Pharma, formerly known as Axcan Pharma until May 2011, is a privately-held specialty pharmaceutical company focused on developing and marketing products for gastrointestinal diseases and disorders. The company addresses conditions such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency. Aptalis aims to enhance the quality of care for patients suffering from these ailments by providing effective therapies tailored to their needs. The company was acquired by TPG Capital in 2008 and expanded its portfolio through the acquisition of Eurand in 2010. Aptalis Pharma is committed to delivering innovative solutions for both patients and their healthcare providers.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

moksha8 Pharmaceuticals, Inc. is a pharmaceutical company that operates in Brazil and Mexico, focusing on the licensing, marketing, and distribution of therapeutics. The company specializes in treatments for various medical fields, including central nervous system disorders, oncology, cardiology, rheumatology, endocrinology, and respiratory conditions. Established in 2006 and based in Berwyn, Pennsylvania, moksha8 has formed strategic alliances with several prominent organizations, including Biopas Laboratories, Roche, Pfizer, BioCryst, and Watson. These partnerships enhance its ability to deliver innovative healthcare solutions in the Latin American market.

Clinical Data, Inc. is focused on the development and commercialization of therapeutics, with two compounds in the areas of central nervous system and cardiovascular disorders. The Company's late-stage drug candidate is vilazodone, a dual-acting selective and potent serotonin reuptake inhibitor and serotonin receptor 1A (5-HT1A) partial agonist for the treatment of major depressive disorder (MDD). The Company's second late-stage drug candidate is apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator in Phase III of clinical development for use in nuclear Single Photo Emission Computed Topography (SPECT) myocardial perfusion imaging. The Company also provides the FAMILION family of genetic tests for inherited cardiac syndromes, including cardiac channelopathies and cardiomyopathies. On September 30, 2009, the Company purchased all the assets of Epix Pharmaceuticals, Inc. (Epix).

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Cerexa is a biopharmaceutical company dedicated to developing innovative anti-infective therapies aimed at treating serious and life-threatening infections. The company's primary focus is on addressing antibiotic-resistant infections, and it offers a portfolio that includes Ceftaroline, an injectable cephalosporin effective against bacterial infections caused by both gram-positive and gram-negative pathogens.